Market Research Logo

Global Schizophrenia Drugs Market: Size, Trends & Forecast (2018-2022)

Global Schizophrenia Drugs Market: Size, Trends & Forecast (2018-2022)

Scope of the Report

The report entitled “Global Schizophrenia Drugs Market: Size, Trends & Forecast (2018-2022)”, provides an in-depth analysis of the global biologics market with description of market sizing and growth. The analysis includes market by value, and market by region. A detailed product analysis of schizophrenia drugs is also provided in the report.

The report includes a brief regional/country analysis of the US, European Union and Japan with their actual and forecasted market size. The U.S. has the largest stake in the global schizophrenia market over the years and is expected to maintain its position in the upcoming years also. Among the Asian countries, Japan is the largest market and has the potential to grow steadily over the forecasted period.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global schizophrenia drugs market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global schizophrenia drugs market is dominated by major players. Eli Lilly & Company, Otsuka Holdings Co., Ltd., Johnson & Johnson, and Alkermes plc are some of the key players operating in the global market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the respective companies are provided.

Company Coverage

Eli Lilly & Company
Otsuka Holdings Co., Ltd.
Johnson & Johnson
Alkermes plc

Executive Summary

Schizophrenia is considered as one of the severe mental disorder that hinders the person’s capacity to think clearly, decision-making, inability to handle emotions etc. It is highly complex in nature as it cannot be easily determined and considered as a long-term illness. Schizophrenia can affect in any phase of life but mostly found in person aged between 20-40 years.

The global schizophrenia drugs market has shown rising trends over the past few years and anticipations are made that the market would grow at a steady pace in the next four years i.e. 2018 to 2022, particularly due to increasing prevalence of schizophrenia globally. The global schizophrenia market is supported by various growth drivers such as increasing number of patients seeking treatment, rising healthcare expenditure, improvement in healthcare infrastructure etc.

Yet the market growth is restrained by some challenges like side-effects associated with drugs, major expiration of patented drugs, and social stigma of mental health conditions. In the coming years, the market would be primarily driven by technological advancements, new products launch, increasing utilization of long-acting injectable antipsychotics.


1. Executive Summary
2. Introduction
2.1 Mental Disorder: An Overview
2.1.1 Types of Mental Disorders
Table 1: Types of Mental Disorders
2.2 Psychotic Disorder: An Overview
2.2.1 Psychotic Disorder: Definition
2.3 Schizophrenia: An Overview
2.3.1 Schizophrenia: Definition
2.3.2 Causes of Schizophrenia
Table 2: Causes of Schizophrenia
2.3.3 Symptoms of Schizophrenia
Table 3: Symptoms of Schizophrenia
2.3.4 Treatment of Schizophrenia
3. Global Market Analysis
3.1 Global Schizophrenia Drugs Market Analysis
3.1.1 Global Schizophrenia Drugs Market by Value
Table 4: Global Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Table 5: Global Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
3.1.2 Global Schizophrenia Drugs Market by Region
Table 6: Global Schizophrenia Drugs Market by Region; 2017 & 2022
4. Product Analysis
4.1 Global Schizophrenia Long-Acting Injectables Product Analysis
4.1.1 ABILIFY MAINTENA (Aripiprazole)
Table 7: ABILIFY MAINTENA Global Sales; 2016-2017 (US$ Million)
4.1.2 INVEGA SUSTENNA (Paliperidone Palmitate)
Table 8: INVEGA SUSTENNA Global Sales; 2015-2017 (US$ Billion)
4.1.3 RISPERDAL CONSTA (Risperidone)
Table 9: RISPERDAL CONSTA Global Sales; 2015-2017 (US$ Million)
4.1.4 ZYPREXA RELPREV (Olanzapine)
Table 10: ZYPREXA RELPREV Global Sales; 2015-2017 (US$ Million)
4.1.5 ARISTADA ((Aripiprazole Lauroxil)
Table 11: The U.S. ARISTADA Sales; 2016-2018E (US$ Million)
5. Regional Market Analysis
5.1 The U.S. Schizophrenia Drugs Market Analysis
5.1.1 The U.S. Schizophrenia Drugs Market by Value
Table 12: The U.S. Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Table 13: The U.S. Schizophrenia Drugs Market by Value; 2018-2022E
(US$ Billion)
5.2 European Union Schizophrenia Drugs Market Analysis
5.2.1 European Union Schizophrenia Drugs Market by Value
Table 14: European Union Schizophrenia Drugs Market by Value; 2012-2017
(US$ Billion)
Table 15: European Union Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
5.3 Japan Schizophrenia Drugs Market Analysis
5.3.1 Japan Schizophrenia Market by Value
Table 16: Japan Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Table 17: Japan Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Increasing Number of Patients Seeking Treatment
6.1.2 Growing Awareness of Mental Healthcare
6.1.3 Rising Healthcare Spending
Table 18: Global Health Care Spending; 2015-2020 (US$ Trillion)
6.1.4 Improvement in Healthcare Infrastructure
6.2 Challenges
6.2.1 Side-effects Associated with Drugs
6.2.2 Social Stigma of Mental Health Conditions
6.2.3 Major Expiration of Patented Drug
6.2.4 Achieving Treatment Adherence
6.3 Market Trends
6.3.1 New Products Launch
Table 19: Promising Compounds in Clinical Development for the Treatment of Schizophrenia in Adults
6.3.2 Increasing Utilization of Long-Acting Injectable Antipsychotics
6.3.3 Availability of Drugs with Novel Mechanism of Action (MoA)
7. Competitive Landscape
7.1 Global Schizophrenia Drugs Market Competitive Landscape
Table 20: Global Schizophrenia Drugs Competitive Landscape by Products
7.2 Global Schizophrenia Drugs Market by Players
Table 21: Global Schizophrenia Market Players by Drugs Sales; 2017 (US$ Million)
8. Company Profiles
8.1 Eli Lilly & Company
8.1.1 Business Overview
8.1.2 Financial Overview
Table 22: Eli Lily & Company Revenue; 2013-2017 (US$ Billion)
Table 23: Eli Lily & Company Revenue by Segments; 2017
Table 24: Eli Lily & Company Revenue by Geography; 2017
8.1.3 Business Strategy
8.2 Otsuka Holdings Co., Ltd.
8.2.1 Business Overview
Table 25: Otsuka Group - Pipeline Information
Table 26: Key Marketed Products for Schizophrenia
8.2.2 Financial Overview
Table 27: Otsuka Holdings Co., Ltd. Net Sales; 2013-2017 (US$ Billion)
8.2.3 Business Strategy
8.3 Johnson & Johnson
8.3.1 Business Overview
8.3.2 Financial Overview
Table 28: Johnson & Johnson Net Sales; 2013-2017 (US$ Billion)
Table 29: Johnson & Johnson Sales by Segments; 2017
Table 30: Johnson & Johnson Sales by Geography; 2017
8.3.3 Business Strategy
8.4 Alkermes plc
8.4.1 Business Overview
Table 31: Key Marketed Products
Table 32: Alkermes Development Pipeline Overview
8.4.2 Financial Overview
Table 33: Alkermes plc Revenue; 2013-2017 (US$ Million)
Table 34: Alkermes plc Revenue by Segments; 2017
Table 35: Alkermes plc Revenue by Geography; 2017
8.4.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report